Relpain Vet - Meloxicam | VetSafeCare.Com

Bol.

Relpain Vet

Meloxicam — Navana Pharmaceuticals Ltd.
100mg Meloxicam

Alternatives

14

Routes

PO

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Bolus · 100mg Meloxicam

100 mg

৳6

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Cat

0.05 mg/kg q24h PO, with a reduction in dose if chronic treatment is pursued. Long-term treatment may be reduced to 0.03 mg/kg q24h or 0.05 mg/kg q48h to 0.05 mg/kg q72h PO.
• Single doses of 0.15–0.3 mg/kg SQ may be administered for short-term use. The manufacturer does not recommend a second dose of meloxicam injection to cats.

Horse

0.6 mg/kg q24h IV or PO. In foals younger than 7 weeks of age, the frequency may be increased to 0.6 mg/kg q12h because of more rapid clearance

Cattle

0.5 mg/kg q24h IV, IM, or SQ.

Dog

0.2 mg/kg initial loading dose PO, SQ, or IV and then 0.1 mg/kg q24h thereafter PO, SQ, or IV.
Oral transmucosal spray (bioequivalent to oral suspension): 0.1 mg/kg sprayed in the dog’s mouth once per day.

Human

For Adults: Osteoarthritis: 7.5 mg/day. If necessary, in the absence of improvement, the dose may be increased to 15 mg/day. Rheumatoid arthritis: 15 mg/day. In elderly patients the recommended dose for long term treatment is 7.5 mg/day. Ankylosing spondylitis: 15 mg/day. In elderly patients the recommended dose is 7.5 mg/day. Do not exceed the dose of 15 mg/day. The total daily amount should be taken as a single dose. Patients with increased risks for adverse reactions should start treatment with 7.5 mg/day. In dialysis patients with severe renal failure the dose should not exceed 7.5 mg/dayFor Children: The pharmacokinetics of Meloxicam in paediatric patients under 18 years of age have not been investigated.

Swine

0.4 mg/kg IM, which may be repeated in 24 hours.

Sheep and Goat

1 mg/kg, single dose, IV, IM, SQ, or PO.

Clinical notes

Applications:
  • Spondylitis
Indication Notes:
Meloxicam is indicated in- Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis
Avoid In:

N/A

Contraindication Notes:
Meloxicam is contraindicated to patients hypersensitive to this drug. Meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or NSAIDs. Meloxicam is contraindicated to patients with active peptic ulcer during the last six months or a history of recurrent peptic ulcer disease, severe hepatic failure, non-dialysed severe renal failure, gastrointestinal bleeding, cerebrovascular bleeding or other bleeding disorders.
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam family, with anti-inflammatory, analgesic and antipyretic properties. The bioavailability of Meloxicam following oral administration is 89% on the average. With the doses of 7.5 mg & 15 mg plasma concentrations are proportional to dose: 0.4 to 1.0 mg/litre for 7.5 mg & 0.8 to 2.0 mg/litre for 15 mg, on an average. Meloxicam is very strongly bound to plasma proteins, essentially albumin (99%). Meloxicam is extensively metabolised, chiefly by oxidation of the methyl redical attached to the thiazolyl ring. Elimination in unchanged form accounts for 3% of the dose. Half of the substance is eliminated in urine & the other half in the faeces. The mean elimination half life is 20 hours.
Other NSAIDs, including high doses of salicylates: Administration of several NSAIDs together may increase the risk of ulcers and of gastrointestinal bleeding, via a synergistic effect. Oral anticoagulants, heparin and ticlopidine: Increased risk of bleeding via inhibition of platelet function and damage to the gastroduodenal mucosa. Careful monitoring of the effects of anticoagulants is thus essential if it proves impossible to avoid such combined prescription. Lithium: NSAIDs increase blood lithium levels, which may then reach toxic values. Methotrexate: NSAIDs may accentuate the haematologic toxicity of methotrexate. Intrauterine contraceptive devices: NSAIDs appear to decrease the efficacy of intrauterine contraceptive devices.
Nausea, vomiting, abdominal pain, dyspepsia, constipation or diarrhoea may occur. Ulcers or gastrointestinal bleeding may rarely occur. Skin rash, or urticaria may occur in some individuals. Oedema of the lower limbs may occur during treatment. Onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other NSAIDs. Headache, vertigo or drowsiness may occur.
It is advisable to avoid the administration of Meloxicam during pregnancy. It is unknown whether Meloxicam passes into mother’s milk. Meloxicam should not be given to nursing mothers.
Patient with known CV disease or risk factors for CV disease, fluid retention or heart failure, history of GI bleeding or ulceration. Hepatic and renal impairment. Elderly. Pregnancy and lactation.